At present, the cultivation of traditional Chinese medicine is still based on the family and needs large-scale development.

In the recommendations of the 13th five-year Plan issued on November 3, 2015, emphasis is placed on the promotion of traditional Chinese medicine and ethnic medicine in medicine. According to data released by the Ministry of Industry and Information Technology, in the first half of this year, the operating income of owners of enterprises above the scale of the pharmaceutical industry increased by 8.91% compared with the same period last year, while the growth rate of traditional Chinese medicine enterprises was 5.2%. In recent years, there has been a craze for the cultivation of traditional Chinese medicine all over the country, and with the continuous expansion of the planting area, the problems such as backward planting technology, pesticide residues and backward patterns are becoming more and more obvious.

At present, the cultivation of traditional Chinese medicine is still based on the family, and the ability to resist natural risk or market risk is relatively weak. In order to solve the anti-risk ability of planting Chinese medicinal materials, many producing areas of Chinese medicinal materials have begun to try to develop in a group. It is understood that many pharmaceutical farmers choose varieties that have previous planting experience and want to be able to make short-term profits, and then there are varieties with government subsidies. Market changes affect the cultivation of traditional Chinese medicine due to natural disasters and other factors leading to a sharp rise in the price of traditional Chinese medicine, medicine farmers follow the trend of planting, so that the planting area is also on the rise; on the contrary, no one is interested. In terms of scale, there has been a pattern of setting up Chinese medicine cooperatives or planting bases in various places. In this way, a unified sales channel can be opened up and the anti-risk ability of traditional Chinese medicine planting can be greatly enhanced. Some producing areas even began to dock directly with pharmaceutical companies, carrying out "order-to-order" planting, skipping the intermediate link of pharmaceutical merchants. In the face of the increasingly stringent control of drugs by the state, in order to ensure drug quality, many proprietary Chinese medicine manufacturers are actively building their own GAP production bases. It can be seen that the large-scale cultivation of traditional Chinese medicine will be the direction of development in the future.

Although the domestic planting area of traditional Chinese medicine has been expanding in recent years, the domestic traditional Chinese medicine market seems to have fallen into a trough and there is no sign of a rebound, while China's exports of traditional Chinese medicine fell by 7.5% in the first half of this year compared with the same period last year, which aggravates the current situation that supply exceeds demand. Therefore, traditional Chinese medicine needs large-scale development and standardization in order to lay a solid foundation for the current depressed market, and only in this way can there be a real spring blooming of traditional Chinese medicine.